Kenneth D. Eichenbaum Acquires 4,000 Shares of InfuSystem Holdings, Inc. (NYSE:INFU) Stock

InfuSystem Holdings, Inc. (NYSE:INFU) Director Kenneth D. Eichenbaum purchased 4,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The shares were acquired at an average cost of $5.89 per share, for a total transaction of $23,560.00. Following the completion of the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $23,560. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

InfuSystem Trading Up 10.2 %

NYSE:INFU opened at $6.57 on Friday. The firm has a market cap of $140.07 million, a P/E ratio of -657,000.00 and a beta of 1.46. InfuSystem Holdings, Inc. has a 52 week low of $5.74 and a 52 week high of $10.99. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.07 and a quick ratio of 1.64.

InfuSystem (NYSE:INFU) last posted its earnings results on Thursday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). The business had revenue of $33.70 million during the quarter. InfuSystem had a return on equity of 0.70% and a net margin of 0.28%.

Institutional Investors Weigh In On InfuSystem

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of InfuSystem by 1.7% during the first quarter. Vanguard Group Inc. now owns 1,083,730 shares of the company’s stock valued at $9,288,000 after acquiring an additional 18,432 shares in the last quarter. Wasatch Advisors LP raised its holdings in InfuSystem by 3.4% in the fourth quarter. Wasatch Advisors LP now owns 846,609 shares of the company’s stock worth $8,923,000 after buying an additional 27,881 shares during the last quarter. Ranger Investment Management L.P. lifted its stake in shares of InfuSystem by 4.7% in the fourth quarter. Ranger Investment Management L.P. now owns 689,842 shares of the company’s stock worth $7,271,000 after buying an additional 30,835 shares in the last quarter. First Eagle Investment Management LLC grew its holdings in shares of InfuSystem by 10.0% during the second quarter. First Eagle Investment Management LLC now owns 666,048 shares of the company’s stock valued at $4,549,000 after buying an additional 60,813 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in InfuSystem by 6.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock valued at $641,000 after acquiring an additional 5,391 shares in the last quarter. Institutional investors own 71.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 20th. B. Riley initiated coverage on InfuSystem in a research report on Thursday. They set a “buy” rating and a $13.00 price target on the stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.